Prescription drug

Procaps Group Reports Record First Quarter 2021 Financial Results

Thursday, May 13, 2021 - 9:01pm

Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.

Key Points: 
  • Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
  • Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
  • Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
  • A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements.

TroyRx Delivers More Prescription Savings and Options to Patients Through Partnership with RxSense

Thursday, May 13, 2021 - 6:00pm

b'CANONSBURG, Pa., May 13, 2021 /PRNewswire-PRWeb/ --TroyRx, an industry leader in prescription software solutions, today announces a partnership with RxSense, the healthcare technology company improving transparency and access to affordable medications.

Key Points: 
  • b'CANONSBURG, Pa., May 13, 2021 /PRNewswire-PRWeb/ --TroyRx, an industry leader in prescription software solutions, today announces a partnership with RxSense, the healthcare technology company improving transparency and access to affordable medications.
  • RxSense\'s technology will help to power TroyRx\'s prescription discount card, OptionRx and enable consumers and patients to save up to 80% on their prescriptions at thousands of retail pharmacies nationwide.
  • Available in both printed and digital formats, OptionRx savings help inform uninsured and underinsured patients of their best affordability options.
  • "Our new partnership with RxSense grows our patient centric network infrastructure, increases the value it can bring to more patients, and improves the prescription experience for providers and their patients on complex therapies.

Covanta Assists Local Connecticut Law Enforcement on National Prescription Drug Take Back Day

Thursday, May 13, 2021 - 2:00pm

To combat this alarming fact, Covanta, a state leader in sustainable waste disposal partnered with local law enforcement in Bristol, West Hartford, Meriden and Berlin, Connecticut to collect unwanted and expired medications in honor of the DEA\'s National Prescription Drug Take Back Day .

Key Points: 
  • To combat this alarming fact, Covanta, a state leader in sustainable waste disposal partnered with local law enforcement in Bristol, West Hartford, Meriden and Berlin, Connecticut to collect unwanted and expired medications in honor of the DEA\'s National Prescription Drug Take Back Day .
  • We\'re proud to partner with local law enforcement and have our waste-to-energy facilities play a critical role in this very important initiative.
  • "\nCovanta has been providing safe disposal of medications collected at community-sponsored, drug take-back programs for over ten years, working with local and federal law enforcement.
  • With a nationwide network of treatment, recycling and Waste-to-Energy facilities, Covanta Environmental Solutions enables customers to mitigate risk and reach their sustainability goals.

Procaps Group to Report First Quarter 2021 Financial Results on May 13, 2021 After the Market Close

Tuesday, May 11, 2021 - 1:31pm

Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.

Key Points: 
  • Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
  • Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
  • Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
  • A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements.

Capital Rx and 3 Axis Advisors Study Finds Potential for Billions in Prescription Drug Savings With Transparent Pricing Practices

Tuesday, May 11, 2021 - 1:00pm

The full study results are available here .\nPotential legislative changes could expand pharmacies\xe2\x80\x99 retail survey reporting of NADAC.

Key Points: 
  • The full study results are available here .\nPotential legislative changes could expand pharmacies\xe2\x80\x99 retail survey reporting of NADAC.
  • Utilizing NADAC is free on a public website, increasing transparency and visibility into actual average retail drug acquisition price.\nMatthew Gibbs, Pharm.
  • D., President of Commercial Markets at Capital Rx, said, \xe2\x80\x9cThis study clearly shows that greater transparency with prescription drug pricing practices could create billions of dollars in savings for patients and payers.
  • Capital Rx has been utilizing NADAC pricing as a foundation for our Clearinghouse Model for over three years.

Rx Savings Solutions Introduces AdminRx For Care Coordination

Thursday, May 6, 2021 - 2:00pm

This results in increased time on the phone, manual entry errors and delays in member outreach.

Key Points: 
  • This results in increased time on the phone, manual entry errors and delays in member outreach.
  • "\nRx Savings Solutions offers an innovative, patented engagement software system empowering employers and employees to be educated consumers of healthcare.
  • Serving more than 9 million members nationwide, including 41 Fortune 500 clients and more than a dozen health plans, Rx Savings Solutions provides a state-of-the-art approach to pharmacy transparency using objective and unbiased information to inform better decision making.
  • Rx Savings Solutions was founded and is operated by a team of pharmacists and software engineers who support a collaborative, cost-saving solution for purchasing prescription drugs.

Biofrontera reports preliminary revenue for the month of April 2021

Thursday, May 6, 2021 - 12:23pm

Ameluz\xc2\xae has been marketed in the EU since 2012 and in the United States since May 2016.

Key Points: 
  • Ameluz\xc2\xae has been marketed in the EU since 2012 and in the United States since May 2016.
  • In addition, the company markets the prescription medication Xepi\xc2\xae for the treatment of impetigo in the United States.
  • Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements.
  • The Company does not undertake an obligation to update or revise any forward-looking statement.\n'

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Tuesday, May 4, 2021 - 10:30pm

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

LifeMD to Release First Quarter 2021 Financial Results on Thursday, May 13, 2021

Tuesday, May 4, 2021 - 1:00pm

LifeMD\'s telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient\'s home.

Key Points: 
  • LifeMD\'s telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient\'s home.
  • Forward-looking statements are inherently subject to risks, uncertainties and assumptions.
  • Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others.
  • All forward-looking statements attributable to LifeMD, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.\n'

Biofrontera AG: First quarter conference call to be held on May 12, 2021

Monday, May 3, 2021 - 2:40pm

The company\xe2\x80\x99s lead product is the combination of Ameluz\xc2\xae, a topical prescription drug, and medical device BF-RhodoLED\xc2\xae for the photodynamic therapy of certain superficial skin cancers and their precursors.

Key Points: 
  • The company\xe2\x80\x99s lead product is the combination of Ameluz\xc2\xae, a topical prescription drug, and medical device BF-RhodoLED\xc2\xae for the photodynamic therapy of certain superficial skin cancers and their precursors.
  • Ameluz\xc2\xae has been marketed in the EU since 2012 and in the United States since May 2016.
  • In addition, the company markets the prescription medication Xepi\xc2\xae for the treatment of impetigo in the United States.
  • The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann L\xc3\xbcbbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.